MedTrace Logo

Dose-Intense Temozolomide in Recurrent Glioblastoma

NCT00657267 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2014-03-14

Study results available
· View outcomes & findings →

Summary

Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed glioblastomas. In this study, we will be using temozolomide to treat recurrent glioblastomas. We will be using a different dose and schedule than the FDA approved dose and schedule. The purpose of this study is to determine if patients that have failed standard temozolomide treatment will respond to temozolomide when given at a different dose and schedule (21 days every 28 days).

Conditions

Interventions

DRUG

Temozolomide

Taken orally daily for the first three weeks of a four-week cycle.

Sponsors & Collaborators

  • Brigham and Women's Hospital

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • University of Pennsylvania

    collaborator OTHER

  • Wake Forest University Health Sciences

    collaborator OTHER

  • Tufts Medical Center

    collaborator OTHER

  • Dartmouth-Hitchcock Medical Center

    collaborator OTHER

  • Schering-Plough

    collaborator INDUSTRY

  • Patrick Y. Wen, MD

    lead OTHER

Principal Investigators

  • Patrick Wen, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-11-30
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00657267 on ClinicalTrials.gov